CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Mannose 6-phosphate receptor, new target for prostate cancer diagnosis

Référence

06100-01

Statut des brevets

French priority patent application n° 14 50588 filed on January 23rd, 2014 and entitled “Nouvelle méthode de dépistage du cancer de la prostate”

Inventeurs

Marcel GARCIA
Ophélie VAILLANT
Xavier REBILLARD, et al.

Statut commercial

Exclusive or non-exclusive License

Laboratoire

Institut des Biomolecules Max Mousseron (IBMM, UMR5247) Montpellier, France

Description

CONTEXT

Prostate cancer is the most common cancer in France and is the fourth leading cause of mortality. The health authorities highlight the need of new tissue marker identifying early forms of prostate cancer to complete the current diagnostic assays. They also stressed the importance of markers to distinguish aggressive forms from indolent forms.

TECHNICAL DESCRIPTION

The overexpression of the cation-independent mannose 6-phosphate receptor (CI-M6PR also known as Insulin like growth factor 2 receptor) is demonstrated in malignant prostatic cells by immunohistochemistry on paraffin embedded tissue sections.

DEVELOPMENT STAGE

The detection of CI-M6PR (IGF2R) in human prostatic tissues is conducted by a conventional immunohistochemistry method on paraffin embedded tissue biopsies. For this purpose we use our in house produced polyclonal antibody. The clinical study was realized on a cohort of 167 patients (including 41 healthy patients). 84% of the cancer positive patients were positive for CI-M6PR expression, including early cancer development stage (Gleason grade 4). No expression of CI-M6PR was observed on healthy tissues.

BENEFITS

The present invention provides a specific marker for prostate cancer diagnosis
Since CI-RM6P is overexpressed only in malignant part of the prostatic tissue (not in normal prostate tissue).

INDUSTRIAL APPLICATIONS

Production of a new clinical kit for the early diagnosis of prostate cancer in multiple tissue biopsies

For further information, please contact us (Ref 06100-01)        

Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents